SB265610 inhibited growth of CT26-sgControl allografts, as evidenced by reduced tumor volume (P < 0.001) and weight (P < 0.05), but had no effect on Slc-KO tumors (Fig. 4j). Here, CCL21 is linked to neoplasm.